Corey Leach, OD
Optometrist · Mesa, AZNPI 1427658921
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,144 of the $2,720 with a category attached, or 78.8%. 14 manufacturers reported payments, led by Visioneering Technologies, Inc. at 27.0% of the total. Reporting peaked in 2023 at $1,378 and has fallen 63.6% since, to $502 in 2024.
Across 59 payments — averaging $46.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Visioneering Technologies, Inc.$734
- Coopervision Inc.$438
- Bausch & Lomb Americas Inc.$422
- Sun Pharmaceutical Industries Inc.$224
- Eyevance Pharmaceuticals LLC$215
- Alcon$208
- plus $477 from 8 others
What the payments were for
- Speaking & faculty fees$50018%
- Food & beverage$2,14479%
- Education$763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Visioneering Technologies, Inc. | 5 | $734 |
| Coopervision Inc. | 10 | $438 |
| Bausch & Lomb Americas Inc. | 14 | $422 |
| Sun Pharmaceutical Industries Inc. | 7 | $224 |
| Eyevance Pharmaceuticals LLC | 2 | $215 |
| Alcon | 7 | $208 |
| Johnson & Johnson Vision Care, Inc. | 3 | $167 |
| Amgen(2 entities) | 2 | $142 |
| Biotissue Holdings Inc. | 2 | $51 |
| Novartis | 2 | $30 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Thea Pharma Inc. | 1 | $21 |
| Synergeyes, Inc. | 2 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tobradex ST$139
- MyDay Contact Lens$139
- Acuvue$125
- CEQUA$123
- TEPEZZA$122
- Precision 1$120
- INFUSE$104
- Multiple Brands Contact Lens$102
How this compares
$2,720 in reported general payments places this provider in the 80th percentile of 1,134 optometrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 16 | $806 |
| Latanoprost | 59 | $657 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $363 |
| Brimonidine Tartrate | 21 | $95 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Mesa
- Kerry PearsonMesa$10K
- Matthew PalmerMesa$8K
- Frank AkersMesa$7K
- Marc BloomensteinScottsdale$1.4M
- Stephanie WooLake Havasu City$538K
- Jashpal RajasansiGilbert$104K
- Jamie KuhnGlendale$37K
- Tania SobchukLake Havasu City$32K
- Stephen CohenScottsdale$32K
- Andrew ZagelbaumScottsdale$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.